Besins Healthcare

What Besins Healthcare does

Besins Healthcare is a privately held, family-owned global pharmaceutical company headquartered in Monaco and founded in 1885, now led by its fifth generation. The company specializes in the development, manufacturing, and commercialization of bioidentical hormone replacement therapies, with a particular focus on transdermal gel delivery systems for estradiol, testosterone, and progesterone. Its portfolio includes category-defining brands such as Progestogel (1972, world's first hormone therapy gel), Oestrogel (1975, first estradiol gel for menopausal disorders), Utrogestan (1980, micronized natural progesterone), and Androgel (2000, described as the most prescribed testosterone gel worldwide). The company maintains an active R&D pipeline covering women's health (endometriosis, fertility, miscarriage, bacterial vaginosis, menopause, HSDD) and men's health (testosterone deficiency).

The business operates five state-of-the-art manufacturing sites across France (Montrouge), Belgium (Drogenbos, producing 1,600 tonnes of hormonal gels annually), Spain (Muel, opened September 2023), Russia (Yaroslavl), and Brazil (Jundiaí). Distribution reaches over 90 countries through a hybrid model combining direct subsidiaries in 22 countries with a network of international distributors. Primary customer segments are women's health (menopause, fertility, pregnancy support) and men's health (testosterone deficiency, hypogonadism), served primarily through prescribing healthcare professionals.

Revenue is generated through prescription pharmaceutical product sales (gels, capsules, tablets) distributed globally, complemented by food supplements and medical devices, and a newer direct-to-consumer subscription platform called The HRT Club (launched April 2024) offering hormone replacement therapies in the U.S. at under $50/month — a deliberate bypass of pharmacy benefit managers and traditional wholesalers. The company also runs educational and brand-building programs including the Besins Hormone Academy, IMS webinar sponsorship, PREIS School partnership, and Andrology Research Academy to deepen HCP engagement. As a fully family-controlled private company with no external investors, Besins Healthcare reports no public revenue or funding data.

Name

Besins Healthcare

Legal name

Besins Healthcare Monaco S.A.M.

Website

https://besins-healthcare.com

Company type

Private

Founded year

1885

Operating status

Operating

Headcount range

51–100 employees

Short description

Besins Healthcare is a privately held, family-owned global pharmaceutical company founded in 1885 that develops, manufactures, and distributes bioidentical hormone replacement therapies — primarily transdermal gels for estradiol, testosterone, and progesterone — to healthcare professionals and patients across more than 90 countries.

Ownership category

akta.pro rank

Product category

Hormone Replacement Therapy Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industries

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN), Male Reproductive & Sexual Medicine (Andrology) (HLAKAOAD), Reproductive Endocrinology & Infertility (Endocrine) (HLAKADAI)

Keywords

• Hormone replacement therapy
• Transdermal hormone gels
• Menopause treatments
• Testosterone replacement therapy
• Reproductive health pharmaceuticals

Headquarters

HQ city

Monaco

HQ country

Germany

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Hormone Products: Development and commercialization of prescription hormone replacement therapies for menopause, fertility, obstetrics, and testosterone deficiency. Products include gels, capsules, and tablets distributed globally through subsidiaries and distributors.
2. HRT Club (Direct-to-Consumer): Direct-to-consumer subscription platform launched April 2024 offering hormone replacement therapies at up to 90% lower cost than traditional U.S. pharmacies. Members pay under $50/month.
3. Food Supplements and Medical Devices: Complementary therapies including food supplements (Ogestan, Inversion Femme, Andractiv) and medical devices supporting hormone imbalances.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels8 records

Core offering

Besins Healthcare develops, manufactures, and commercializes prescription hormone replacement therapies, with a focus on transdermal gels for estradiol, testosterone, and bioavailable progesterone. Its portfolio addresses women's health (menopause, fertility, obstetrics) and men's health (testosterone deficiency), distributed globally through subsidiaries and a distributor network in over 90 countries.

Differentiator

Problem solved

Functional benefit

Brands

• The HRT Club: Direct-to-consumer HRT platform launched April 2024, bypassing pharmacy benefit managers and insurance companies to offer hormone replacement therapies at up to 90% lower cost than traditional U.S. pharmacies
• Besins Hormone Academy

Products and services

• Progestogel World's first hormone therapy gel (progesterone gel 1%) for transdermal use, indicated for hormone therapy in women.
• Oestrogel First estradiol gel (0.06%) in pump-pack form for transdermal use, indicated for treatment of menopausal disorders.
• Utrogestan Micronised natural progesterone in soft vaginal or oral capsules (100mg, 200mg, 300mg), used in hormone therapy and reproductive medicine.
• Androgel Testosterone gel in pump or sachets (1%; 1.62%) for transdermal use, indicated for male hormone replacement; the most prescribed testosterone gel worldwide.
• The HRT Club Direct-to-consumer subscription platform that bypasses pharmacy benefit managers, insurance companies, and large wholesalers to offer hormone replacement therapies at lower cost. Currently serves over 1,000 prescribing healthcare professionals and adds approximately 200 new members weekly.
• Ogestan Food supplement supporting women's health and hormone balance.
• Inversion Femme Food supplement for women addressing hormonal imbalances.
• Andractiv Food supplement supporting men's health and hormone balance.

Quantifiable outcome

• 1,600 tonnes of hormonal gels produced annually from Belgium facility alone
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core, minor and major.

• PREIS School (International and European School of Perinatal, Neonatal and Reproductive Medicine)coreStrategic or Co-development PartnerSince 2013, Besins Healthcare has funded 136 courses through PREIS School with an average of 460 attendees per year from 42 different nations. Courses are taught by 62 expert speakers and held globally including New York, Mexico City, Buenos Aires, Detroit, Athens, Venice, St Petersburg, Rome, Beijing, Sydney, Dubai, Berlin and Bangkok. Partnership aims to elevate standard of perinatal, neonatal and reproductive healthcare worldwide.
• International Menopause Society (IMS)coreStrategic or Co-development PartnerThrough an unrestricted educational grant, Besins Healthcare sponsors monthly IMS webinars since 2020 to present to provide highly scientific and clinically relevant up-to-date information to healthcare professionals on women's health during different stages of menopause.
• Andrology Research Academy (AReA)coreStrategic or Co-development PartnerVirtual forum for scientific exchange in andrology and men's health with over 1,000 registered users from over 45 countries. Besins Healthcare sponsors virtual seminars, webinars and symposiums to support collaboration among researchers and healthcare professionals.
• Postgraduate International School of Men's Health (PRISM)minorStrategic or Co-development PartnerPrestigious institution providing interdisciplinary training in men's health. Besins Healthcare supports healthcare professionals' attendance at PRISM ensuring access to latest research and clinical practices.
• Monaco Rugby 7minorGTM or Marketing PartnerChampions of France 2022 in Rugby Sevens. Besins Healthcare is a dedicated partner sharing values of trustworthiness, passion, caring, open-mindedness, teamwork and entrepreneurial spirit. Company celebrates their victory and promotes sports and health in the community.
• Women's Health Ambassadors (Isabelle and Audrey)minorGTM or Marketing PartnerTwo adventurers sponsored to participate in Rallye Aïcha des Gazelles du Maroc, promoting women's health values, empowerment, and eco-responsibility across Sahara dunes with an electric buggy.
• BILD NewspapermajorGTM or Marketing PartnerBesins Healthcare Germany partnered with Germany's largest daily newspaper for major women's health event. Co-sponsored by Roche. Event revealed €9.4 billion in annual economic losses in Germany due to absenteeism linked to menopausal symptoms. Nationwide media coverage focused on menopause awareness and bioidentical hormone treatments.
• RocheminorGTM or Marketing PartnerCo-sponsor with Besins Healthcare for BILD newspaper women's health event in Germany.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Theramex: Private global specialty pharma focused exclusively on women's health, particularly menopause, contraception, and fertility. Closely comparable to Besins in therapeutic focus, prescriber base, and global distribution model.
• Endo International: Specialty pharma with historic leadership in testosterone replacement (e.g., AndroGel prior to genericization) and women's health. Most direct historical competitor to Besins' Androgel franchise in the US.
• Gedeon Richter: Hungarian-headquartered specialty pharma with a strong women's health portfolio (contraception, menopause, fertility) and broad CEE and Western European distribution. Closely comparable in therapeutic categories and private-to-public hybrid ownership profile.
• Organon & Co. Public women's health spinoff from Merck with established franchises in fertility, contraception, and menopause hormone therapy. Direct competitor across Besins' core reproductive health and HRT product lines.
• TherapeuticsMD (now part of Pfizer): US-focused women's health company commercializing hormone therapy products including BIJUVA and ANNOVERA. Directly comparable therapeutic focus on bioidentical hormone therapies, though currently undergoing acquisition by Pfizer.

Broad incumbents

• Novo Nordisk: Global leader in hormone-related therapies (insulin, GLP-1, hormone replacement) with deep endocrinology expertise and infrastructure. Operates at vastly larger scale but competes for the same prescriber relationships and endocrinology expertise.
• AbbVie: Global pharma giant whose portfolio includes androgens and women's health adjacencies, and which competes for the same physician prescribers. Significantly larger and broader, but overlaps in hormone-related indications.
• Bayer (Women's Health / Pharma): Large incumbent pharma with established hormone therapy franchises (e.g., Climara estradiol patch) and global women's health infrastructure. Competes in the same prescriber and patient pool but as part of a much broader portfolio including crop science and consumer health.

Emerging players

• Mithra Pharmaceuticals: Belgian women's health specialty pharma with products in contraception, menopause (Estelle), and vaginal health. Comparable in size, therapeutic focus, and European base, though smaller and earlier-stage commercially.

Regional players

• Ipsen: European specialty pharma with adjacent therapeutic franchises including endocrinology and women's health. Comparable in scale, private-to-public governance style, and European distribution strength.

Market position

Strengths5 records

Competitive moat5 records

Key risks1 record

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCz0kzqSxN1UgQLhqp5zox6A
• Facebookfacebook.com/profile.php?id=61551373923068
• LinkedInlinkedin.com/company/besins-healthcare
• Instagraminstagram.com/besins.healthcare

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Besins Healthcare